current
expect
privat
sector
race
sar
immedi
invest
consider
resourc
fasttrack
develop
plan
candid
vaccin
larg
uncharacter
pathogen
unknown
origin
unknown
perspect
constant
threat
novel
emerg
diseas
well
recogn
scientif
commun
public
health
author
privat
sector
scenario
effici
crisi
manag
rapid
effect
diseas
control
exampl
influenza
pandem
develop
world
health
organ
global
influenza
program
european
commun
us
center
diseas
control
atlanta
howev
prior
current
situat
countri
implement
strateg
plan
nation
level
scenario
fortun
never
valid
global
scale
importantli
next
undisput
practic
strateg
plan
next
influenza
pandem
start
current
interpandem
period
good
level
prepared
appropri
nation
supran
structur
may
posit
affect
speed
effici
respons
emerg
diseas
pandem
potenti
current
outbreak
sever
acut
respiratori
syndrom
sar
unpreced
exampl
emerg
viral
diseas
global
scale
besid
dramat
consequ
crisi
import
lesson
learnt
world
commun
capabl
appropri
reaction
novemb
novel
pathogen
unknown
origin
characterist
start
spread
among
human
popul
china
reach
least
three
contin
within
short
period
time
effici
control
outbreak
initi
phase
imped
lack
knowledg
etiolog
diseas
consequ
reluct
inadequ
measur
taken
local
nation
author
high
profil
sar
intern
news
media
contribut
earli
public
diseas
awar
also
caus
fear
affect
unaffect
popul
place
addit
polit
econom
pressur
author
act
threat
despit
insuffici
basi
inform
decis
intern
organ
promin
play
crucial
role
intern
coordin
local
support
control
measur
well
inform
knowhow
manag
global
scale
outbreak
becam
fulli
appar
scientif
commun
support
commit
develop
vaccin
pathogen
sever
imped
current
fragmentari
inform
viral
pathogen
lack
adequ
anim
model
correl
protect
human
unparallel
collabor
effort
within
short
period
time
novel
coronaviru
sarscov
establish
caus
sar
knowledg
novel
viru
continu
expand
breathtak
speed
almost
daili
basi
consequ
focuss
measur
could
taken
prevent
spread
viru
treat
sar
patient
howev
travel
restrict
improv
diagnost
tool
hygien
measur
remain
main
instrument
control
spread
sar
current
june
day
outbreak
diseas
report
sar
case
death
shortterm
measur
prove
instrument
control
pandem
rapid
avail
diagnost
test
well
develop
specif
therapeut
drug
vaccin
depend
commit
pharmaceut
industri
becam
serious
involv
time
caus
agent
identifi
april
us
health
author
held
meet
invit
washington
dc
usa
individu
present
gather
select
global
vaccin
manufactur
urg
use
everi
endeavour
rapid
develop
candid
vaccin
sar
agent
inde
view
report
rapid
larg
uncontrol
spread
diseas
three
contin
situat
appear
request
drastic
emerg
plan
includ
implement
broad
rang
technolog
maxim
chanc
success
wherea
necess
global
respons
global
threat
appear
painstakingli
obviou
everybodi
includ
privat
industri
decisionmak
situat
vaccin
manufactur
deal
occas
rather
unusu
current
expect
privat
sector
race
sar
immedi
invest
consider
resourc
fasttrack
develop
plan
candid
vaccin
larg
uncharacter
pathogen
unknown
origin
unknown
perspect
classic
industri
decisionmak
process
initi
new
develop
project
therapeut
drug
vaccin
reli
care
analysi
seri
premis
qualiti
relev
result
collect
exploratori
research
phase
particularli
identif
correct
immunogen
formul
eventu
adjuv
vaccin
effect
establish
anim
model
appropri
rout
applic
chanc
safe
effect
human
profit
calcul
exampl
net
present
valu
breakeven
point
return
invest
base
upon
estim
potenti
market
time
reach
exist
competit
likelihood
success
uniqu
strategi
exist
intellectu
properti
ip
potenti
gener
new
ip
particular
critic
aspect
initi
new
project
necessari
competit
resourc
infrastructur
ongo
research
develop
portfolio
especi
hold
true
use
pilot
gmp
facil
ie
soon
clinic
lot
manufactur
case
sar
risk
associ
develop
vaccin
increas
time
pressur
due
limit
basi
knowledg
pathogen
may
appropri
rememb
usual
timetomarket
new
drug
vaccin
year
start
earli
feasibl
research
phase
includ
preclin
process
immunolog
profil
develop
clinic
develop
registr
well
manufactur
plant
plan
setup
therefor
even
due
special
emerg
situat
timelin
preclin
clinic
develop
may
shorten
question
remain
whether
need
product
time
readi
market
specif
spite
fortun
capabl
propag
sarscov
wellaccept
cell
substrat
vero
develop
vaccin
pathogen
sever
imped
current
fragmentari
inform
viral
pathogen
lack
adequ
anim
model
persist
infect
correl
protect
human
origin
sarscov
still
unclear
anim
close
contact
human
like
sourc
sens
sarscov
possibl
realli
novel
viru
rather
newli
discov
one
follow
adapt
new
host
speci
name
human
despit
potenti
coronavirus
mutat
rapidli
cross
speci
barrier
known
strain
gener
speciesspecif
genet
stabl
asid
human
coronavirus
found
mammal
pig
cat
dog
cattl
mous
bird
chicken
caus
wide
varieti
diseas
respiratori
gastrointestin
hepat
immunopatholog
depend
speci
pathogen
potenti
coronavirus
vari
moder
deadli
mutat
occur
cours
infect
dramat
alter
virul
document
felin
coronaviru
fecv
sever
veterinari
vaccin
anim
coronavirus
market
experi
product
provid
use
inform
design
sarscov
vaccin
instanc
number
vaccin
infecti
bronchiti
viru
ibv
wide
use
chicken
farm
cattl
bovin
coronaviru
bcv
vaccin
administ
pregnant
cow
order
protect
newborn
calv
sever
diarrhea
presum
via
matern
antibodi
cat
vaccin
via
mucos
rout
liveattenu
fecv
hand
preexist
antibodi
fecv
cat
necessarili
protect
even
aggrav
diseas
via
antibodydepend
enhanc
ade
infect
exist
veterinari
vaccin
base
classic
vaccin
approach
name
liveattenu
whole
inactiv
virus
administ
either
via
parenter
mucos
rout
despit
numer
hurdl
wait
road
threat
global
emerg
diseas
certainli
justifi
unconvent
highrisk
term
invest
outcom
approach
sar
vaccin
approach
may
seem
attract
first
sight
regard
speed
cost
develop
product
use
success
past
eg
live
attenu
smallpox
oral
polio
measl
rubella
mump
yellow
fever
kill
hepat
influenza
howev
consid
current
regulatori
safeti
cgmp
requir
vaccin
wholeviru
vaccin
approach
associ
signific
drawback
safeti
reason
delic
balanc
attenu
immunogen
genet
stabil
ie
risk
vaccinecaus
diseas
observ
sabin
oral
polio
vaccin
vacciniabas
smallpox
vaccin
manufactur
issu
scaleup
product
safeti
level
reason
subunitor
nucleic
acidbas
approach
would
favor
due
earli
avail
full
viral
genom
sequenc
quick
develop
prototyp
vaccin
candid
base
strategi
similar
hepat
b
surfac
antigen
produc
yeast
express
sar
antigen
wellcharacter
liveattenu
viral
bacteri
vector
may
envisag
howev
even
vaccin
prove
immunogen
may
protect
may
even
lead
ademedi
patholog
order
meet
urgent
demand
sar
vaccin
fasttrack
develop
may
support
parti
involv
bare
risk
safeti
aspect
assess
prior
administr
larg
popul
especi
longterm
thu
main
issu
critic
address
deal
vaccin
safeti
may
summar
two
question
achiev
accept
balanc
request
speed
safeti
aspect
assess
quickli
reliabl
immunogen
efficaci
candid
vaccin
specif
absenc
relev
anim
model
minim
accept
fasttrack
toxic
program
ethic
accept
go
phase
trial
stress
safeti
remain
major
concern
vaccinolog
wellb
vaccine
also
due
fact
public
percept
vaccin
gener
would
strongli
affect
neg
news
safeti
new
vaccin
one
high
benefitrisk
ratio
efficaci
sar
vaccin
would
conclus
global
scientif
commun
react
unpreced
speed
effici
news
unknown
agent
caus
lifethreaten
diseas
emerg
asia
essenti
inform
exampl
genom
sequenc
rapidli
gener
immedi
made
publicli
avail
industri
gener
certainli
readi
rise
challeng
pose
sar
regard
vaccin
particularli
health
author
urg
invest
lot
effort
commerci
highrisk
fasttrack
research
program
inde
despit
numer
hurdl
wait
road
threat
global
emerg
diseas
certainli
justifi
unconvent
highrisk
term
invest
outcom
approach
howev
due
exceedingli
high
possibl
failur
appropri
incent
urgent
need
major
nation
intern
organ
grant
contribut
earli
highrisk
phase
project
feasibl
studi
clinic
phase
ii
may
allow
increas
number
approach
investig
therebi
maxim
overal
chanc
success
undoubtedli
sar
provid
number
valuabl
lesson
manag
futur
emerg
diseas
pandem
potenti
